Fairvalue-Calculator Fairvalue-Calculator
EN DE

Oncoinvent ASA (ONCIN) Fair Value & Analysis

Healthcare · NO · Market cap 206M NOK

Pricekr 49.90
Fair Valuekr 28.73
Upside-42.4%
Quality95/100
Evidence: Low Range kr 18.96 – kr 35.92

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Oncoinvent ASA (ONCIN) currently trades at kr 49.90, while our model-based Fair Value estimate is kr 28.73 — implying the stock looks roughly 42.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. Oncoinvent ASA is based in Oslo, Norway.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Oncoinvent ASA (ONCIN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of kr 28.73 versus a price of kr 49.90 — about −42% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ONCIN?
Our 21-model fair value for Oncoinvent ASA is kr 28.73 (as of Jun 25, 2026), built from audited fundamentals. The current price is kr 49.90.
What is the quality score of ONCIN?
Oncoinvent ASA has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.